Mink Therapeutics, Inc. SEC Filings

Brian Corvese, a director of MiNK Therapeutics, Inc. (INKT), was granted 1,290 restricted stock units (RSUs) on 09/02/2025 as board and committee compensation in lieu of cash. Each RSU represents a contingent right to receive one share of common stock and the grant price shown on the form is $13.86 per share. After the grant, the reporting person beneficially owns 48,441 shares. The RSUs are scheduled to vest one month from the grant date. The Form 4 was signed by an attorney-in-fact on 09/03/2025.

MiNK Therapeutics director Peter Behner received 1,173 restricted stock units (RSUs) on 09/02/2025, granted in lieu of cash board and committee retainers. Each RSU represents a contingent right to one share of common stock and will vest one month from the grant date.

After the grant, Mr. Behner beneficially owns 18,649 shares of MiNK common stock on a direct basis. The reported per-share value associated with the grant is $13.86. The Form 4 was submitted to disclose this change in beneficial ownership.

MiNK Therapeutics (INKT) filed a Form 144 proposing the sale of 786,750 shares of common stock, with an aggregate market value of $12,572,265, to be sold approximately on 08/29/2025 on the INKT exchange. The filing states these shares were originally issued on 07/05/2017 in an original issuance from the issuer when it was a wholly owned subsidiary of Agenus Inc.; the shares were acquired in exchange for Agenus Inc.'s initial capital contribution. The filer reports no securities sold in the past three months and provides the standard representation that no undisclosed material adverse information is known.

MiNK Therapeutics (INKT) reported operational and financing updates in its Form 10-Q. The company completed an Option Exchange that re-priced 647,915 options to an exercise price of $7.43 with a 10-year term and unchanged vesting, producing approximately $0.6 million of incremental share-based compensation expense ($0.4 million recognized immediately and $0.2 million over the remaining vesting period). Agenus-related intercompany activities are disclosed, including a $14.5 million note receivable as of June 30, 2025 that Agenus agreed not to require repayment for the foreseeable future; interest accrues and may convert at Agenus’ election into equity at 80% of a qualified financing price. The company completed a 1-for-10 reverse stock split effective January 28, 2025. Nasdaq compliance for Minimum Value of Listed Securities was restored after MVLS exceeded $35.0 million for the required consecutive period. Clinical highlights include a durable complete remission in a refractory metastatic testicular cancer patient and a durable partial response in an advanced gastric cancer patient following agenT-797 plus checkpoint blockade.

MiNK Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2025 and furnished a related press release as Exhibit 99.1 to this Current Report on Form 8-K. The filing states that the information under Item 2.02 and Exhibit 99.1 is being furnished and therefore is not intended to be deemed filed for purposes of Section 18 of the Exchange Act. The 8-K itself does not include the underlying financial figures; the press release referenced in Exhibit 99.1 contains the detailed results and the Cover Page Interactive Data File is included as Exhibit 104.

MiNK Therapeutics, Inc. (NASDAQ: INKT) filed a Form 8-K announcing that on 15 July 2025 it entered into an At-Market Issuance Sales Agreement with B. Riley Securities. The agreement allows the company to issue and sell up to $50 million of common stock from time to time on the open market.

The shares will be offered under the company’s effective Form S-3 shelf registration (File No. 333-268143) via a base prospectus (dated 8 Nov 2022) and a new prospectus supplement dated 15 July 2025. Sales will be made at prevailing market prices, with B. Riley acting as the agent for placement; compensation terms were not disclosed in this filing.

Exhibits include: (1) the full Sales Agreement (Ex 1.1); (2) the legal opinion and consent of Latham & Watkins LLP (Ex 5.1 & 23.1); and (3) the cover-page Inline XBRL file (Ex 104).

Key Implications for Investors

• The facility provides flexible, immediate access to capital that can support R&D, clinical trials or general corporate purposes without negotiating separate financing rounds.
• Issuances will be executed “at-the-market,” potentially creating incremental selling pressure and dilution as shares are sold into the market.
• The $50 million capacity should be evaluated relative to MiNK’s market capitalisation; if sizeable, ongoing issuance could materially increase the share count.